Proteotype Launches €3 Million European Study to Expand Multi-Cancer Detection Validation
Proteotype has announced the INNOVATOR study, a €3.023 million clinical initiative aimed at expanding validation of its multi-cancer blood test, Enlighten®, across 12 cancer types in Portugal, Spain, and Germany. The project will recruit approximately 2,000 participants—1,200 with cancer and 800 controls—and evaluate the feasibility of using capillary blood samples collected at home. The study is supported by €2.116 million from COMPETE 2030 under Portugal 2030 and co-funded by the European Union. The INNOVATOR project, set to begin on October 1, 2026, will assess whether capillary blood collection can support a future laboratory-based test. It is expected to conclude by late 2028.
Topics: blood-based tests cancer diagnostics home sample collection